With me to answer those questions is a leading dermato-epidemiologist whose clinical research focuses on improving the care of patients with chronic inflammatory skin diseases. She's led several multi ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Individuals with PFB are at increased risk for hypertrophic scarring, keloid scarring, and infection. Pseudofolliculitis barbae is a chronic inflammatory condition, and the only true cure is shaving ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...

New clinical trial data published today in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with ...

Gram-negative folliculitis (GNF) is one of the most common mimics and complications of acne and acne rosacea. First described by Fulton in 1968, 1 GNF in acne patients is a relatively rare ...

Please provide your email address to receive an email when new articles are posted on . A 3-year-old girl came running into her house, crying loudly with pain in her right hand. Her mother noticed ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...